To evaluate the contribution of PTENP1 to reduced breast cancer cell viability in response to the YPB and OPB peptides, we generated two shPTENP1 constructs, which reduced PTENP1 to about 40% of its original level, and carried out the cotreatments by these shRNAs and peptides. This evidence concerns the gene PTENP1 and breast cancer.